Nivolumab (anti-PD-1), atezolizumab (anti-PD-L1), and tremelimumab (anti- CTLA4), have been proved to be safe and have effective anti-tumor responses for treating HCC (93–95). Here, CTLA4 is linked to hepatocellular carcinoma.